Global health authorities require biologically produced material to be tested and negative for mycoplasma because these microscopic organisms can pose a big risk to cell culture, rendering products unsafe and unusable. Implementing and validating a rapid mycoplasma testing method may be entirely new territory for some, while others may be more familiar with these methods and their technicalities. Regardless of the level of experience with rapid mycoplasma testing, most biologics developers and researchers come across a variety of questions and challenges.
The following panel discussion explores some of these questions with insight and potential solutions from experts in the field.
Please check the highlighted fields and try again.
Please fill out the information below to request information on the products you selected. If you are already registered, or have requested a quote before, login and this information will be filled out for you.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.
Please enter the phone number you would like to be contacted at.
By submitting my personal data to CompareNetworks, I acknowledge it will be shared with the Thermo Fisher Scientific group for processing in accordance with the Thermo Fisher Scientific Privacy Policy. I can withdraw my consent and unsubscribe at any time by emailing reply@thermofisher.com.
Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.